Proof of added benefit of apixaban in hip replacement
September 17, 2012 in Medications
The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of apixaban.
IQWiG found proof of minor added benefit for adult patients who had undergone hip replacement: symptomatic clots in the deep veins of the leg occurred less frequently with apixaban treatment than with the comparator therapy.
Symptomatic clots in the deep leg veins also occurred less frequently with apixaban treatment in adults after knee replacement. However participants in the studies suffered clots in the lungs (pulmonary embolisms) more often under treatment with apixaban than the comparator group. From weighing up the benefits and harms (risk of side effects) on the basis of the data presented in the manufacturer's dossier, IQWiG identified no proof of added benefit of apixaban over the appropriate comparator therapy in knee replacement operations.
Enoxaparin as comparator therapy
After the insertion of an artificial hip or knee, there is an increased risk of blood clots (thrombi) that are swept away in the bloodstream and can block a blood vessel in another part of the body. Clots that cause symptoms (symptomatic thromboembolism) may, for instance, occur in the lungs and deep veins of the legs.
Apixaban is approved for the prevention of venous thromboembolism (VTE) in adults following hip or knee replacement surgery. The Federal Joint Committee (G-BA) specified low molecular weight heparins (clot inhibitors), which are approved for the prevention of deep vein thrombosis, as the appropriate comparator therapy. The comparison between apixaban and the drug enoxaparin chosen by the manufacturer in its dossier corresponds to this definition.
Added benefit offset by lesser benefit in knee replacement surgery
Deaths were generally rare in both the relevant studies and mortality with apixaban treatment in hip or knee replacement operations did not differ from that with enoxaparin. With both types of surgery, the incidence of bleeding or other side effects and study withdrawals was also no greater under apixaban than under the comparator therapy. Neither of the relevant studies examined the quality of life.
Both studies showed that apixaban was more effective in preventing symptomatic deep vein thrombosis than the comparator therapy: about one in 1000 patients who took apixaban developed a symptomatic deep vein thrombosis; the figure for patients who injected enoxaparin was about 4 in 1000. A minor added benefit of apixaban is proven in this case.
In hip replacement surgery, there was no difference between the treatment groups in respect of pulmonary embolisms. However after knee replacement, these occurred more frequently under apixaban than under enoxaparin: About 5 in 1000 patients who took apixaban had a pulmonary embolism, compared to about one in 1000 under enoxaparin. This leads to an indication of a lesser benefit of apixaban compared to the comparator therapy. The extent of this lesser benefit was classified as "considerable". From weighing up the benefits and harms on the basis of the data presented in the manufacturer's dossier, IQWiG found no proof of added benefit of apixaban over the appropriate comparator therapy in knee replacement surgery.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
Provided by
Institute for Quality and Efficiency in Health Care
-
Added benefit of linagliptin is not proven
Jan 06, 2012 |
not rated yet |
0
-
Belimumab for lupus erythematosus: Added benefit not proven
Aug 29, 2012 |
not rated yet |
0
-
Added benefit of fampridine is not proven
Aug 29, 2012 |
not rated yet |
0
-
Added benefit of Cannabis sativa for spasticity due to multiple sclerosis is not proven
Sep 17, 2012 |
not rated yet |
0
-
Abiraterone: Indication of considerable added benefit in certain patients
Jan 06, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
19 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
8 hours ago |
3 / 5 (2) |
0
Global recommendations on child medicine
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications
9 hours ago |
not rated yet |
0
Analgesics prescribed more heavily to women than to men, study finds
Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...
Medications
17 hours ago |
not rated yet |
0
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications
May 20, 2013 |
5 / 5 (1) |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
May 20, 2013 |
not rated yet |
0
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.